Drugs / Coptis Chinensis
Coptis Chinensis
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06703788 | Nov 2024 → Jun 2025 overdue | abdominal obesity-metabolic syndrome, diabetes mellitus, hyperlipidemia, obesity disorder | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00704236 | Sep 2006 → Feb 2008 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coptis chinensis | “and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily)” NCT06703788 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “This traditional compound Chinese herb preparation is referred to this study” NCT00704236 ↗ |